Zealand Pharma A/S (NASDAQ:ZEAL) Q3 2019 Earnings Conference Call - Final Transcript

Nov 14, 2019 • 10:00 am ET


Zealand Pharma A/S (NASDAQ:ZEAL) Q3 2019 Earnings Conference Call - Final Transcript


Loading Event

Loading Transcript


Ladies and gentlemen, thank you for standing by and welcome to the Zealand Pharma Results for the Third Quarter of 2019 Conference Call. [Operator Instructions] After the speakers' presentation, there will be a question-and-answer session. [Operator Instructions] I must advise you that this conference is being recorded today, Thursday 14th of November 2019.

And I would now like to hand the conference over to your first speaker today, Ms. Lani Morvan. Please go ahead ma'am.

Lani Morvan

Thank you and welcome to Zealand Pharma's conference call for the third quarter of fiscal year 2019. Leading today's call are Zealand's CEO, Emmanuel Dulac; CFO, Matt Dallas; and Chief Medical and Development Officer, Adam Steensberg.

Emmanuel will provide business highlights from the third quarter and period thereafter. Matt will add financial highlights and Adam will follow with updates from our research and development programs.

After the prepared remarks, we will open the call to take your questions. Joining for the Q&A will be Ivan Moller, Senior Vice President of Technical Development and Operations; Marino Garcia, Senior Vice President of Corporate and Business Development; and Rie Schultz Hansen, Vice President of Research and Interim Chief Scientific Officer.

You can find the Company announcement containing the Q3 Interim Reports and additional supporting information in the Investor section of our website at zealandpharma.com. As a company headquartered in Denmark, our financials are reported in Danish krone, often referred to as kroner. Key figures may have been converted to US dollars for convenience.

On Page 1, I will point out that we will be making forward-looking statements that are subject to risks and uncertainties. These statements are valid only as of today and the Company assumes no obligation to update them except as required by law. Please refer to recent filings for a more complete picture of risks and other factors.

And with Page 2, I will turn the call over to Emmanuel.

Emmanuel Dulac

Thank you, Lani. And thanks to everyone for joining the call today. Zealand Pharma has made impressive progress so far this year. We clarified our strategy and advanced our pipeline. Our existing partnerships were strengthened. New partnerships were secured and our financial strengths was reinforced with a V4 [Phonetic] from a significant private placement, with an existing shareholder.

The accelerated pace of our Company is driven by our highly committed employees and we have added further talent to the team supporting both our recent achievements and long-term value creation.

If you turn to Page 3, you can see how all of these achievements are part of the exciting journey that Zealand is taking with vast opportunities to improve patients' lives by providing leading peptide therapeutics. We have one of the most productive and promising platforms in biotech that has been built over the last 20 years.

Our peptide therapeutics platform and know-how has been repeatedly validated by partnerships with industry leaders and the positive results demonstrated in our late clinical programs. In 2019, we have taken big steps towards our ambition to become a fully integrated